Stuver S, Trichopoulos D. Cancer of the liver and biliary tract. Cancer Epidemiol. 2008;2:308–32.

Google Scholar 

Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–62.

Article  CAS  PubMed  Google Scholar 

Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018.

Article  PubMed  Google Scholar 

Kang SH, Cho Y, Jeong SW, Kim SU, Lee J-W, Group KNS. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: big wave or ripple? Clin Mol Hepatol. 2021;27(2):257.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee SW, Choi J, Kim SU, Lim Y-S. Entecavir versus tenofovir in patients with chronic hepatitis B: enemies or partners in the prevention of hepatocellular carcinoma. Clin Mol Hepatol. 2021;27(3):402.

Article  PubMed  PubMed Central  Google Scholar 

Seo SH, Lee DH, Lee YS, Cho KJ, Park HJ, Lee HW, et al. Co-administration of ursodeoxycholic acid with rosuvastatin/ezetimibe in a non-alcoholic fatty liver disease model. Gastroenterol Rep. 2022;10:goac037.

Article  Google Scholar 

Lee HA, Chang Y, Sung PS, Yoon EL, Lee HW, Yoo J-J, et al. Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases. Clin Mol Hepatol. 2022;28(3):425.

Article  PubMed  PubMed Central  Google Scholar 

Yu JH, Lee HA, Kim SU. Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future. Clin Mol Hepatol. 2023;29(Suppl);S136.

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.

Article  CAS  PubMed  Google Scholar 

Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–73.

Article  CAS  PubMed  Google Scholar 

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–905.

Article  CAS  PubMed  Google Scholar 

Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5(10):835–44.

Article  CAS  PubMed  Google Scholar 

Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.

Article  CAS  PubMed  Google Scholar 

Keating GM. Sorafenib: a review in hepatocellular carcinoma. Target Oncol. 2017;12(2):243–53.

Article  PubMed  Google Scholar 

Han K, Kim JH, Ko G-Y, Gwon DI, Sung K-B. Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: a comprehensive review. World J Gastroenterol. 2016;22(1):407.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hampton T. Cancer drug trials show modest benefit: drugs target liver, gastric, head and neck cancers. JAMA. 2007;298(3):273–5.

Article  CAS  PubMed  Google Scholar 

Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, Niehrs C. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature. 1998;391(6665):357–62.

Article  CAS  PubMed  Google Scholar 

Fedi P, Bafico A, Soria AN, Burgess WH, Miki T, Bottaro DP, et al. Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. J Biol Chem. 1999;274(27):19465–72.

Article  CAS  PubMed  Google Scholar 

Niida A, Hiroko T, Kasai M, Furukawa Y, Nakamura Y, Suzuki Y, et al. DKK1, a negative regulator of Wnt signaling, is a target of the β-catenin/TCF pathway. Oncogene. 2004;23(52):8520–6.

Article  CAS  PubMed  Google Scholar 

Krupnik VE, Sharp JD, Jiang C, Robison K, Chickering TW, Amaravadi L, et al. Functional and structural diversity of the human Dickkopf gene family. Gene. 1999;238(2):301–13.

Article  CAS  PubMed  Google Scholar 

Shen Q, Fan J, Yang X-R, Tan Y, Zhao W, Xu Y, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012;13(8):817–26.

Article  CAS  PubMed  Google Scholar 

Kim SU, Park JH, Kim H-S, Lee JM, Lee HG, Kim H, et al. Serum Dickkopf-1 as a biomarker for the diagnosis of hepatocellular carcinoma. Yonsei Med J. 2015;56(5):1296–306.

Article  CAS  PubMed  PubMed Central  Google Scholar 

He S, Tang S. WNT/β-catenin signaling in the development of liver cancers. Biomed Pharmacother. 2020;132:110851.

Article  CAS  PubMed  Google Scholar 

Yu B, Yang X, Xu Y, Yao G, Shu H, Lin B, et al. Elevated expression of DKK1 is associated with cytoplasmic/nuclear β-catenin accumulation and poor prognosis in hepatocellular carcinomas. J Hepatol. 2009;50(5):948–57.

Article  CAS  PubMed  Google Scholar 

Zhang R, Lin H-M, Broering R, Shi X-D, Yu X-H, Xu L-B, et al. Dickkopf-1 contributes to hepatocellular carcinoma tumorigenesis by activating the Wnt/β-catenin signaling pathway. Signal Transduct Target Ther. 2019;4(1):1–10.

CAS  Google Scholar 

Pandur P, Läsche M, Eisenberg LM, Kühl M. Wnt-11 activation of a non-canonical Wnt signalling pathway is required for cardiogenesis. Nature. 2002;418(6898):636–41.

Article  CAS  PubMed  Google Scholar 

Kimura H, Yamamoto H, Harada T, Fumoto K, Osugi Y, Sada R, et al. CKAP4, a DKK1 receptor, is a biomarker in exosomes derived from pancreatic cancer and a molecular target for therapy. CKAP4 may be a biomarker and a therapeutic target for PDAC. Clin Cancer Res. 2019;25(6):1936–47.

Article  CAS  PubMed  Google Scholar 

Seo SH, Cho KJ, Park HJ, Kim H, Lee HW, Kim BK, et al. Dickkopf-1 promotes angiogenesis by upregulating VEGF receptor 2-mediated mTOR/p70S6K signaling in hepatocellular carcinoma. Am J Cancer Res. 2021;11(10):4788.

CAS  PubMed  PubMed Central  Google Scholar 

Choi SH, Kim H, Lee HG, Kim BK, Park JY, Kim DY, et al. Dickkopf-1 induces angiogenesis via VEGF receptor 2 regulation independent of the Wnt signaling pathway. Oncotarget. 2017;8(35):58974–84.

Article  PubMed  PubMed Central  Google Scholar 

Su T-H, Wu C-H, Liu T-H, Ho C-M, Liu C-J. Clinical practice guidelines and real-life practice in hepatocellular carcinoma: a Taiwan perspective. Clin Mol Hepatol. 2023;29(2):230.

Article  PubMed  PubMed Central  Google Scholar 

Takimoto CH, Awada A. Safety and anti-tumor activity of sorafenib (Nexavar®) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol. 2008;61:535–48.

Article  CAS  PubMed  Google Scholar 

Cervello M, Bachvarov D, Lampiasi N, Cusimano A, Azzolina A, McCubrey JA, et al. Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells. PLoS One. 2013;8(6):e65569.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Atianand MK, Caffrey DR, Fitzgerald KA. Immunobiology of long noncoding RNAs. Annu Rev Immunol. 2017;35:177–98.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ju H-L, Ahn SH, Kim DY, Baek S, Chung SI, Seong J, et al. Investigation of oncogenic cooperation in simple liver-specific transgenic mouse models using noninvasive in vivo imaging. PLoS One. 2013;8(3):e59869.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moon H, Ju H-L, Chung SI, Cho KJ, Eun JW, Nam SW, et al. Transforming growth factor-β promotes liver tumorigenesis in mice via up-regulation of snail. Gastroenterology. 2017;153(5):1378-91.e6.

Article  CAS  PubMed  Google Scholar 

Moon H, Park H, Chae MJ, Choi HJ, Kim DY, Ro SW. Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways. BMC Cancer. 2022;22(1):1–11.

Article  Google Scholar 

Cho K, Ro SW, Seo SH, Jeon Y, Moon H, Kim DY, et al. Genetically engineered mouse models for liver cancer. Cancers. 2019;12(1):14.

Article  PubMed  PubMed Central  Google Scholar 

Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, et al. Sorafenib (BAY 43–9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007;59:561–74.